The role of quality of life data as an endpoint for collecting real-world evidence within geroscience clinical trials
Роль данных о качестве жизни в качестве конечной точки при сборе доказательств из реальной клинической практики в клинических исследованиях геронауки
2024-04-03
SCID: 54.1/9rmvbpv9
Discuss with AI
SF-36geroprotective interventionsgeroscience clinical trialsquality of lifereal-world evidence
Figures from the paper
Abstract (AI)
With geroscience research evolving at a fast pace, the need arises for human randomized controlled trials to assess the efficacy of geroprotective interventions to prevent age-related adverse outcomes, disease, and mortality in normative aging cohorts. However, to confirm efficacy requires a long-term and costly approach as time to the event of morbidity and mortality can be decades. While this could be circumvented using sensitive biomarkers of aging, current molecular, physiological, and digital endpoints require further validation. In this review, we discuss how collecting real-world evidence (RWE) by obtaining health data that is amenable for collection from large heterogeneous populations in a real-world setting can help speed up validation of geroprotective interventions. Further, we propose inclusion of quality of life (QoL) data as a biomarker of aging and candidate endpoint for geroscience clinical trials to aid in distinguishing healthy from unhealthy aging. We highlight how QoL assays can aid in accelerating data collection in studies gathering RWE on the geroprotective effects of repurposed drugs to support utilization within healthy longevity medicine. Finally, we summarize key metrics to consider when implementing QoL assays in studies, and present the short-form 36 (SF-36) as the most well-suited candidate endpoint.
Key Findings
1
Long-term morbidity and mortality endpoints make geroscience randomized trials costly and slow, while existing aging biomarkers still require validation.
2
Quality-of-life assays can accelerate real-world evidence collection on geroprotective effects of repurposed drugs.
3
Quality-of-life measurements are proposed as aging biomarkers and clinical-trial endpoints for distinguishing healthy from unhealthy aging.
4
Real-world evidence from large, heterogeneous populations may accelerate validation of geroprotective interventions.
5
The SF-36 is identified as the most well-suited quality-of-life endpoint for geroscience clinical trials.
Research Object
quality-of-life data in geroscience clinical trials and real-world evidence studies of geroprotective interventions in normative aging cohorts
Research Subject
the role and suitability of quality-of-life measures, particularly SF-36, as biomarkers and endpoints for evaluating geroprotective efficacy and distinguishing healthy from unhealthy aging
Publication Details
Publication Date
2024-04-03
Journal
Publisher
ISSN
Cited by
9
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest